中国医科大学学报

中国医科大学学报
  • 中文核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
  • BA、CA收录

中国医科大学学报 ›› 2018, Vol. 47 ›› Issue (10): 900-904.doi: 10.12007/j.issn.0258-4646.2018.10.008

• 论著 • 上一篇    下一篇

DNMT3a对胰腺癌细胞吉西他滨敏感性的影响

荆薇1, 宋娜2,3, 车晓芳2,3, 侯科佐2,3, 杨向红4   

  1. 1. 中国医科大学附属盛京医院第一肿瘤科, 沈阳 110022;
    2. 中国医科大学附属第一医院肿瘤内科, 沈阳 110001;
    3. 中国医科大学附属第一医院辽宁省肿瘤药物及生物治疗重点实验室, 沈阳 110001;
    4. 中国医科大学附属盛京医院病理科, 沈阳 110004
  • 收稿日期:2018-01-16 出版日期:2018-10-30 发布日期:2018-09-30
  • 通讯作者: 杨向红 E-mail:xhyang4933@vip.sina.com
  • 作者简介:荆薇(1982-),女,主治医师,博士.
  • 基金资助:
    辽宁省高等学校基本科研项目青年项目(LQNK201711)

Effect of DNMT3a on the Chemosensitivity of Pancreatic Cancer Cells to Gemcitabine

JING Wei1, SONG Na2,3, CHE Xiaofang2,3, HOU Kezuo2,3, YANG Xianghong4   

  1. 1. The First Department of Oncology, Shengjing Hospital, China Medical University, Shenyang 110022, China;
    2. Department of Medical Oncology, The First Hospital, China Medical University, Shenyang 110001, China;
    3. Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital, China Medical University, Shenyang 110001, China;
    4. Department of Pathology, Shengjing Hospital, China Medical University, Shenyang 110004, China
  • Received:2018-01-16 Online:2018-10-30 Published:2018-09-30

摘要: 目的 研究DNA甲基转移酶3a(DNMT3a)对胰腺癌Panc-1细胞吉西他滨敏感性的影响,并探讨其作用机制。方法 MTT法检测吉西他滨对人胰腺癌细胞增殖的影响;应用siRNA下调DNMT3a表达;Western blotting确认DNMT3a蛋白敲除效率,检测吉西他滨及siRNA DNMT3a对p-STAT3、STAT3和胞苷脱氨酶(CDA)表达的影响。流式细胞仪检测细胞凋亡。结果 下调DNMT3a表达能够增加胰腺癌Panc-1细胞对吉西他滨的敏感性。下调DNMT3a表达能够降低由吉西他滨引起的p-STAT3和CDA表达上调。下调DNMT3a表达能够增加由吉西他滨诱导的细胞凋亡。结论 下调DNMT3a可以通过抑制CDA及STAT3通路促进胰腺癌细胞吉西他滨的敏感性。

关键词: 药物敏感性, 吉西他滨, 胰腺癌, DNA甲基转移酶3a

Abstract: Objective To evaluate the effect and mechanism of DNA methyltransferase-3a (DNMT3a)on the chemosensitivity of pancreatic cancer cells to gemcitabine (GEM). Methods MTT assay was used to determine the effect of GEM and DNMT3a on the proliferation of pancreatic cancer cell line,Panc-1. Cells were transfected with siRNA to downregulate the expression of DNMT3a. The expression of DNMT3a,CDA,p-STAT3s,and STAT3 in PANC-1 cells transfected with siDNMT3a were detected by Western blotting. Flow cytometry was used to detect apoptosis. Results Downregulation of DNMT3a expression increased the sensitivity of Panc-1 cells to GEM,reduced the upregulation of p-STAT3 and CDA expression induced by GEM,and increased the apoptosis induced by GEM. Conclusion Downregulation of DNMT3a expression increased the chemosensitivity of pancreatic cancer cells to GEM by inhibiting the activation of STAT3 and expression of CDA.

Key words: chemosensitivity, gemcitabine, pancreatic cancer, DNA methyltransferase-3a

中图分类号: 

  • R735.9
[1] SIEGEL RL,MILLER KD,JEMAL A. Cancer statistics,2017[J]. CA Cancer J Clin,2017,67(1):7-30. DOI:10.3322/caac.21387.
[2] LIN QJ,YANG F,JIN C,et al. Current status and progress of pancreatic cancer in China[J]. World J Gastroenterol,2015,21(26):7988-8003. DOI:10.3748/wjg.v21.i26.7988.
[3] ROSSI MK,GNANAMONY M,GONDI CS. The ‘SPARC’ of life:analysis of the role of osteonectin/SPARC in pancreatic cancer[J]. Int J Oncol,2016,48(5):1765-1771. DOI:10.3892/ijo.2016.3417.
[4] SCHULTHEIS B,REUTER D,EBERT MP,et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active firstline regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer:a multicenter,randomized phase Ⅱb study[J]. Ann Oncol,2017,28(10):2429-2435. DOI:10.1093/annonc/mdx343.
[5] GREENHALF W,GHANEH P,NEOPTOLEMOS JP,et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial[J]. J Nat Cancer Institute,2014,106(1):347. DOI:10.1093/jnci/djt347.
[6] GNANAMONY M,GONDI CS. Chemoresistance in pancreatic cancer:emerging concepts[J]. Oncol Lett,2017,13(4):2507-2513. DOI:10.3892/ol.2017.5777.
[7] GARCIA-GARCIA AB,GOMEZ-MATEO MC,HILARIO R,et al. mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival[J]. Oncotarget,2017,8(62):104796-104805. DOI:10.18632/oncotarget.20076.
[8] AUNG KL,FISCHER SE,DENROCHE RE,et al. Genomics-driven precision medicine for advanced pancreatic cancer-early results from the COMPASS trial[J]. Clin Cancer Res,2017,24(6):1344-1354. DOI:10.1158/1078-0432.CCR-17-2994.
[9] ZHANG JJ,ZHU Y,ZHU Y,et al. Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma[J]. Clin Translational Oncol, 2012,14(2):116-124. DOI:10.1007/s12094-012-0770-x.
[10] FEINBERG AP,VOGELSTEIN B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts[J]. Nature,1983,301(5895):89-92.
[11] OUADID-AHIDOUCH H,RODAT-DESPOIX L,MATIFAT F,et al. DNA methylation of channel-related genes in cancers[J]. Biochimica Biophysica Acta,2015,1848(10 Pt B):2621-2628. DOI:10.1016/j.bbamem.2015.02.015.
[12] HE S,WANG F,YANG L,et al. Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer[J]. PLoS One, 2011,6(11):e27684. DOI:10.1371/journal.pone.0027684.
[13] JING W,SONG N,LIU Y,et al. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53 deficient pancreatic cancer cells[J]. Mol Med Rep, 2018,17(1):117-124. DOI:10.3892/mmr.2017.7923.
[14] BURRIS HA RD,MOORE MJ,ANDERSEN J,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J]. J Clin Oncol,1997,15(6):2403-2413. DOI:10.1200/JCO.1997.15.6.2403.
[15] ADAMSKA A,ELASKALANI O,EMMANOUILIDI A,et al. Molecular and cellular mechanisms of chemoresistance in pancreatic cancer[J]. Adv Biol Regul,2018,68(1):77-87. DOI:10.1016/j.jbior.2017.11.007.
[16] VENKATASUBBARAO K,PETERSON L,ZHAO S,et al. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer[J]. Mol Cancer,2013,12(1):104. DOI:10.1186/1476-4598-12-104.
[17] DE SOUSA CAVALCANTE L,MONTEIRO G. Gemcitabine:metabolism and molecular mechanisms of action,sensitivity and chemoresistance in pancreatic cancer[J]. Eur J Pharmacol,2014,741(1):8-16. DOI:10.1016/j.ejphar.2014.07.041.
[18] YOON KA,WOO SM,HONG EK,et al. Cytidine deaminase as a molecular predictor of gemcitabine response in patients with biliary tract cancer[J]. Oncology,2015,89(6):345-350. DOI:10.1159/000439222.
[1] 荣辰, 田素飞, 褚云卓. 326株念珠菌血症病原菌种分布和药敏结果分析[J]. 中国医科大学学报, 2018, 47(9): 773-777.
[2] 马刚, 刘宁, 徐亮, 刘哲, 宋从浩, 王丹璞. 程序性细胞死亡因子4与5-氟尿嘧啶对胰腺癌细胞凋亡的协同作用[J]. 中国医科大学学报, 2018, 47(5): 431-434.
[3] 康可歆 ,李昱骥. 载药胶束改善吉西他滨对胰腺癌的治疗效果[J]. 中国医科大学学报, 2017, 46(3): 281-283.
[4] 于雪,刘妍,奚奇,万成福,董道松,赵林,宋涛. 经膈脚后间隙穿刺损毁内脏神经治疗胰腺癌疼痛的临床疗效分析[J]. 中国医科大学学报, 2016, 45(4): 301-304.
[5] 高威,盛伟伟,董明,周建平. 胰腺癌术后肝转移的临床病理学特点[J]. 中国医科大学学报, 2015, 44(7): 644-648.
[6] 刘一,李亚明,李娜,李雪娜,杜补林. 18F?FDG PET/CT在胰腺良恶性病变的诊断及鉴别诊断中的价值[J]. 中国医科大学学报, 2014, 43(6): 547-558.
[7] 王春晖,乔宠,周文平,麻树仁. KiSS?1基因对人胰腺癌Capan?2细胞的增殖及侵袭的影响[J]. 中国医科大学学报, 2014, 43(4): 304-312.
[8] 李建军,顾菲,李光,乔俏. 后程加量三维适形放疗同步化疗治疗局部晚期胰腺癌的疗效观察[J]. 中国医科大学学报, 2013, 42(12): 1113-1116.
[9] 林琳, 哈敏文 . 低剂量延时输注吉西他滨维持治疗晚期非小细胞肺癌临床分析 [J]. 中国医科大学学报, 2012, 41(2): 184-184.
[10] 李光,于洋洋,韩冲,乔俏,党军,顾菲,李建军,姚雷. 81例胰腺癌后程加量三维适形放疗的疗效分析[J]. 中国医科大学学报, 2012, 41(12): 1134-1137.
[11] 许元鸿,刘哲,郭克建,杜瑞霞,蒋红军. 新基因JDP2通过不同通路抑制人胰腺癌上皮向间质转化作用的研究[J]. 中国医科大学学报, 2012, 41(11): 990-994.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王月, 徐振华, 苏荣健. 外分泌葡萄糖调节蛋白78对肝细胞癌侵袭的影响[J]. 中国医科大学学报, 2018, 47(7): 589 -592 .
[2] 杜国强, 王立银, 王晓凤, 李君, 张明明, 王瑾. APE1通过NF-κB通路调节PD-L1在喉鳞状细胞癌中的表达[J]. 中国医科大学学报, 2018, 47(10): 865 -870 .
[3] 张然, 汤艳清, 魏胜男, 王菲. 伴自杀意念重性抑郁障碍患者的弥散张量成像[J]. 中国医科大学学报, 2018, 47(10): 871 -875 .
[4] 林莉, 殷典贺, 韩丹, 侯刚, 尹燕, 康健, 王秋月. 熊果酸对香烟烟雾诱导大鼠肺气肿及氧化应激的影响[J]. 中国医科大学学报, 2018, 47(10): 876 -880 .
[5] 李冬阳, 李智, 曲晶磊, 曲秀娟, 刘云鹏. NFκB活化受体因子在胃癌中的表达及临床意义[J]. 中国医科大学学报, 2018, 47(10): 881 -885,890 .

中国医科大学学报版权所有©2018

未经允许,严禁擅自转载本站图文资料

地址:中国 沈阳市沈北新区蒲河路77号 110122

辽ICP备05014850

JOURNAL OF CHINA MEDICAL UNIVERSITY

ADDRESS: NO.77 PUHE ROAD

SHENYANG NORTH NEW AREA, SHENYANG

LIAONING PROVINCE, P.R. CHINA